MIRA PHARMACEUTICALS, INC. (MIRA) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, MIRA PHARMACEUTICALS, INC.'s filing signal continuing negative.

MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing novel oral therapeutics for neurologic, neuropsychiatric, metabolic, and addiction-related disorders. The company holds exclusive rights in the U.S., Canada, and Mexico for three drug candidates: Ketamir-2, a next-generation oral NMDA receptor modulator targeting neuropathic pain; MIRA-55, a preclinical cannabinoid analog for inflammatory pain and CNS disorders; and SKNY-1, a preclinical therapeutic for metabolic and addiction-related conditions. Ketamir-2 has completed Phase 1 trials and is preparing for a Phase 2a study in chemotherapy-induced peripheral neuropathy. MIRA-55 and SKNY-1 are in preclinical development, with IND-enabling activities underway. The company aims to address significant unmet medical needs in these therapeutic areas.

The company has not generated revenue and expects to fund its development activities through existing cash, potential new debt and equity financing, and proceeds from an ATM offering. Monetization of product candidates is anticipated at the end of planned Phase II studies.